
    
      An open-label extension study to assess the safety and tolerability of SEP-363856 in subjects
      with schizophrenia This is an open-label extension study to evaluate long-term safety and
      tolerability of SEP-363856. This is a 52-week, outpatient, multicenter, flexible-dose,
      open-label extension study designed to evaluate the long-term safety and tolerability of
      SEP-363856 (25 to 100 mg/day) for the treatment of subjects with schizophrenia who have
      completed the Treatment Period of one of the two following double-blind studies: Study
      SEP361-301 or Study SEP361-302.
    
  